Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;76(Suppl 2):S166-S178.
doi: 10.1093/cid/ciad109.

Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex

Mariana Castanheira  1 , Rodrigo E Mendes  1 , Ana C Gales  2
Affiliations

Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex

Mariana Castanheira et al. Clin Infect Dis. .

Abstract

Acinetobacter baumannii-calcoaceticus complex is the most commonly identified species in the genus Acinetobacter and it accounts for a large percentage of nosocomial infections, including bacteremia, pneumonia, and infections of the skin and urinary tract. A few key clones of A. baumannii-calcoaceticus are currently responsible for the dissemination of these organisms worldwide. Unfortunately, multidrug resistance is a common trait among these clones due to their unrivalled adaptive nature. A. baumannii-calcoaceticus isolates can accumulate resistance traits by a plethora of mechanisms, including horizontal gene transfer, natural transformation, acquisition of mutations, and mobilization of genetic elements that modulate expression of intrinsic and acquired genes.

Keywords: A. baumannii-calcoaceticus complex; epidemiology; international clones; resistance mechanisms.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest . A. C. G. has been partially supported by the National Council for Scientific and Technological Development (CNPq; process number: 312066/2019-8). A. C. G. has recently received research funding and/or consultation fees from bioMérieux, Eurofarma, Merck & Co, Inc, Pfizer, Roche, Sandoz, and United Medical. M. C. and R. E. M are employees of JMI Laboratories, which was contracted to perform services in 2022 for AbbVie, Inc; AimMax Therapeutics; Amicrobe, Inc; Appili Therapeutics; Armata Pharmaceuticals; Astellas Pharma, Inc; Basilea Pharmaceutica AG; Becton, Dickinson and Company; bioMérieux; Biosergen AB; Bugworks; Cerba Research NV; Cidara Therapeutics; Cipla USA, Inc; ContraFect Corporation; CorMedix, Inc; Crestone, Inc; Curza Global, LLC; Diamond V; Discuva Ltd; Entasis Therapeutics; Enveda Biosciences; Evopoint Biosciences; Fedora Pharmaceuticals; Fox Chase Chemical Diversity Center; Genentech; Gilead Sciences, Inc; GSK plc; Institute for Clinical Pharmacodynamics; Iterum Therapeutics plc; Janssen Biopharma; Johnson & Johnson; Kaleido Biosciences; LifeMine Therapeutics; Medpace, Inc; Lysovant Sciences, Inc; Meiji Seika Pharma; Melinta Therapeutics; Menarini Group; Merck & Co; MicuRx Pharmaceutical, Inc; Mundipharma International Ltd; Mutabilis; Nabriva Therapeutics; National Cancer Institute; National Institutes of Health; Ohio State University; Omnix Medical Ltd; Paratek Pharmaceuticals; Pfizer; PolyPid Ltd; PPD; Prokaryotics, Inc; Pulmocide Ltd; Qpex Biopharma; Revagenix; Roche Holding AG; Roivant Sciences; Scynexis, Inc; SeLux Diagnostics; Shionogi & Co, Ltd; Sinovent Pharmaceuticals, Inc; Spero Therapeutics; Sumitovant Biopharma, Inc; TenNor Therapeutics; ThermoFisher Scientific; US Food and Drug Administration; VenatoRx Pharmaceuticals; Washington University; Watershed Medical, LLC; Wockhardt; and Zoetis, Inc. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. Brisou J, Prevot A R. Studies on bacterial taxonomy. X. The revision of species under Acromobacter group. Ann Inst Pateur (Paris) 1954; 86:722–728. - PubMed
    1. Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J Bacteriol 1968; 95:1520–41. - PMC - PubMed
    1. Lessel E. Subcommittee on the Nomenclature of Moraxella and Allied Bacteria. Int J Syst Bacteriol 1971; 21:213–4.
    1. Lautrop H. Bergey's manual of determinative bacteriology. Baltimore, MD: Williams & Wilkins Co, 1974.
    1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538–82. - PMC - PubMed

Publication types

MeSH terms

Substances